Universal reference book for medicines

Active substance: nonappropriate

Type: antitussive drug with anti-bronchoconstrictive action

Composition, form of production and packaging
? Tablets for resorption of flat-cylindrical shape, with a risk and chamfer, from white to almost white. On the flat side, the inscription MATERIA MEDICA is marked with a risk, on the other flat side there is inscription RENGALIN.
1 tab.

antibodies to bradykinin 0.006 g *

antibodies to histamine 0.006 g *

antibodies to morphine 0.006 g *

* are applied to lactose in the form of a mixture of three active hydroalcoholic dilutions of the substance diluted 100-12, 100 30 , 100 200 times, respectively.

[PRING] isomalt 0.506 g, microcrystalline cellulose 0.0275 g, magnesium stearate 0.0055 g, citric acid anhydrous 0.005225 g, silicon dioxide colloid 0.00275 g, sodium cyclamate 0.00275 g, sodium saccharin 0.000275 g.

10 pieces.
- Cellular outline packaging (aluminum / PVC) (1) - cardboard packs.
10 pieces.
- Cellular outline packaging (aluminum / PVC) (2) - cardboard packs.
10 pieces.
- Cellular outline packaging (aluminum / PVC) (5) - cardboard packs.

Description of the drug approved by the manufacturer for the printed edition of 2015.


It has been shown experimentally that the components of the preparation modify the activity of ligand-receptor interaction of endogenous regulators with corresponding receptors: antibodies to morphine - with opiate receptors;
antibodies to histamine - with H 1 -histamine receptors; antibodies to bradykinin - with B 1 -receptors of bradykinin; while the combined use of components leads to an increase in the antitussive effect.
In addition to antitussive action, the complex drug due to its components has anti-inflammatory, anti-edematous, antiallergic, spasmolytic (antibodies to histamine, antibodies to bradykinin) and analgesic action (antibodies to morphine).

The complex preparation Rengalin due to modification of histamine-dependent activation of H 1 -receptors and bradykinin-dependent activation of B 2 receptors selectively reduces the excitability of the cough center of the medulla oblongata, inhibits the central links of the cough reflex.
Inhibiting the centers of pain sensitivity in the thalamus, blocks transmission of pain impulses to the cerebral cortex. Inhibits the flow of painful impulses from the periphery due to a decrease in the release of tissue and plasma algogens (histamine, bradykinin, prostaglandins, etc.). Unlike narcotic analgesics does not cause respiratory depression, drug dependence, does not possess narcogenic and hypnotic effects.
It alleviates the manifestations of acute pharyngitis, laryngitis and bronchitis, reducing bronchospasm.
It relieves systemic and local symptoms of allergic reactions by influencing the synthesis and release of histamine and bradykinin from mast cells.

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, chromatography-mass spectrometry) does not allow to estimate the content of ultra-small doses of antibodies in biological fluids, organs and tissues, which makes it technically impossible to study the pharmacokinetics of the Rengalin preparation.


- acute and chronic diseases of the respiratory tract, accompanied by cough and bronchospasm;

- productive and unproductive cough with influenza and SARS, acute pharyngitis, laryngotracheitis, acute obstructive laryngitis, chronic bronchitis and other infectious and inflammatory and allergic diseases of the upper and lower respiratory tract.


At one time - 1 table. (keep in your mouth until completely dissolved). Use 1-2 tablets 3 times a day outside meals. Depending on the severity of the condition in the first three days, the frequency of admission can be increased to 4-6 times a day.

Possible reactions of increased individual sensitivity to the components of the drug.


- increased individual sensitivity to the components of the drug.

Rengalin is not recommended for use in children under the age of 3 due to inadequate data on efficacy and safety.


The safety of the use of Rengalin in pregnant women and during breastfeeding has not been studied.
If necessary, taking the drug should take into account the risk / benefit ratio.

Rengalin does not affect the ability to drive vehicles and other potentially dangerous mechanisms.


In case of an accidental overdose, dyspepsia is possible due to the excipients included in the formulation.


There have been no incidents of incompatibility with other drugs to date.


Without recipe.


In the dark place at a temperature of no higher than 25 В° C.
Keep out of the reach of children. Shelf life - 3 years. Do not use after the expiration date.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!